What is the share price of Aarti Pharmalabs Ltd (AARTIPHARM) today?
The share price of AARTIPHARM as on 15th July 2025 is ₹950.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Aarti Pharmalabs Ltd (AARTIPHARM) share?
The past returns of Aarti Pharmalabs Ltd (AARTIPHARM) share are- Past 1 week: 2.57%
- Past 1 month: 3.33%
- Past 3 months: 37.30%
- Past 6 months: 42.78%
- Past 1 year: 53.71%
- Past 3 years: N/A%
- Past 5 years: 223.61%
What are the peers or stocks similar to Aarti Pharmalabs Ltd (AARTIPHARM)?
The peers or stocks similar to Aarti Pharmalabs Ltd (AARTIPHARM) include:What is the dividend yield % of Aarti Pharmalabs Ltd (AARTIPHARM) share?
The current dividend yield of Aarti Pharmalabs Ltd (AARTIPHARM) is 0.54.What is the market cap of Aarti Pharmalabs Ltd (AARTIPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹8454.40 Cr as of 15th July 2025.What is the 52 week high and low of Aarti Pharmalabs Ltd (AARTIPHARM) share?
The 52-week high of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹949.50 and the 52-week low is ₹551.05.What is the PE and PB ratio of Aarti Pharmalabs Ltd (AARTIPHARM) stock?
The P/E (price-to-earnings) ratio of Aarti Pharmalabs Ltd (AARTIPHARM) is 31.04. The P/B (price-to-book) ratio is 4.81.Which sector does Aarti Pharmalabs Ltd (AARTIPHARM) belong to?
Aarti Pharmalabs Ltd (AARTIPHARM) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Aarti Pharmalabs Ltd (AARTIPHARM) shares?
You can directly buy Aarti Pharmalabs Ltd (AARTIPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Aarti Pharmalabs Ltd
AARTIPHARM Share Price
950.901.94% (+18.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AARTIPHARM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AARTIPHARM Performance & Key Metrics
AARTIPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.03 | 4.81 | 0.54% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.43 | 6.45 | 0.80% |
AARTIPHARM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
AARTIPHARM Company Profile
Aarti Pharmalabs Ltd manufactures active pharmaceutical ingredients and intermediates, offering CDMO services for drug development and production, with a focus on oncology and corticosteroid products.
DIVISLAB
PE Ratio
82.13
82.13
1Y Return
48.15%
48.15%
Buy Reco %
50.00
50.00
SYNGENE
PE Ratio
51.52
51.52
1Y Return
14.54%
14.54%
Buy Reco %
71.43
71.43
PE Ratio
1,208.54
1,208.54
1Y Return
48.86%
48.86%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
29.77
29.77
1Y Return
75.71%
75.71%
Buy Reco %
0.00
0.00
BROOKS
PE Ratio
-45.70
-45.70
1Y Return
87.75%
87.75%
Buy Reco %
0.00
0.00
AARTIPHARM Sentiment Analysis
AARTIPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AARTIPHARM Stock Summary · May 2025
Aarti Pharma demonstrated robust financial performance in FY25, with a 14% increase in full-year revenues and a notable 26% rise in profit after tax, driven by strong operational cash flow and margin expansion. The company is strategically expanding its capacity, particularly in the Xanthine segment, while also focusing on high-margin products in regulated markets to enhance profitability. Despite facing competitive pressures and pricing challenges, especially in the CDMO sector, management remains optimistic about future growth, projecting a 30-40% revenue increase in this segment for FY26. Sustainability initiatives and a commitment to R&D further position the company favorably, aligning with long-term growth strategies and market demands. Overall, Aarti Pharma is poised for continued success, leveraging its diverse product portfolio and strategic market focus.
AARTIPHARM Stock Growth Drivers
AARTIPHARM Stock Growth Drivers
7Strong Financial Performance
The company achieved significant financial milestones in FY25, reporting revenues of Rs. 2,113 crores, a
Operational Excellence and Capacity Expansion
The company has made significant strides in operational efficiency, with a focus on capacity expansion.
AARTIPHARM Stock Challenges
AARTIPHARM Stock Challenges
6Decline in Aarti USA Business
The business of Aarti USA is expected to decline, with a reported topline of approximately
Negative Other Income and Forex Losses
The company reported negative other income for the quarter, attributed to forex losses resulting from
AARTIPHARM Forecast
AARTIPHARM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
AARTIPHARM
AARTIPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
AARTIPHARM Income Statement
AARTIPHARM Income Statement
Annual Normal View
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 1,202.45 | 1,947.55 | 1,857.51 | 2,125.19 | 2,125.20 | ||||||
Raw Materials | 0.00 | 686.72 | 1,295.12 | 1,040.67 | 1,650.70 | 1,650.70 | ||||||
| Power & Fuel Cost | 44.14 | 75.10 | 84.03 | |||||||||
| Employee Cost | 85.20 | 121.32 | 128.03 | |||||||||
| Selling & Administrative Expenses | 27.35 | 110.28 | 97.65 | |||||||||
| Operating & Other expenses | 149.58 | 1.37 | 116.19 | |||||||||
EBITDA | 0.00 | 209.46 | 344.36 | 390.94 | 474.49 | 474.50 | ||||||
| Depreciation/Amortization | 0.00 | 42.12 | 62.54 | 73.24 | 86.90 | 86.91 | ||||||
| PBIT | 0.00 | 167.34 | 281.82 | 317.70 | 387.59 | 387.59 | ||||||
| Interest & Other Items | 0.00 | 11.96 | 21.05 | 17.21 | 26.90 | 26.89 | ||||||
| PBT | 0.00 | 155.38 | 260.77 | 300.49 | 360.69 | 360.70 | ||||||
| Taxes & Other Items | 0.00 | 33.13 | 67.28 | 83.59 | 88.29 | 88.28 | ||||||
| Net Income | 0.00 | 122.25 | 193.49 | 216.90 | 272.40 | 272.42 | ||||||
| EPS | 0.00 | 4,890.00 | 42.58 | 23.93 | 30.06 | 30.06 | ||||||
| DPS | 0.00 | 0.00 | 2.00 | 3.00 | 5.00 | 3.50 | ||||||
| Payout ratio | — | 0.00 | 0.05 | 0.13 | 0.17 | 0.12 |
AARTIPHARM Company Updates
FY 2025FY 2025
Investor Presentation
May 12PDF
AARTIPHARM Stock Peers
AARTIPHARM Past Performance & Peer Comparison
AARTIPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation-basic on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aarti Pharmalabs Ltd | 31.04 | 4.81 | 0.54% |
| Divi's Laboratories Ltd | 82.13 | 13.26 | 0.44% |
| Syngene International Ltd | 51.52 | 5.41 | 0.20% |
| Dishman Carbogen Amcis Ltd | 1,208.54 | 0.70 | — |
AARTIPHARM Stock Price Comparison
Compare AARTIPHARM with any stock or ETFCompare AARTIPHARM with any stock or ETF
AARTIPHARM
AARTIPHARM Holdings
AARTIPHARM Shareholdings
AARTIPHARM Promoter Holdings Trend
AARTIPHARM Promoter Holdings Trend
AARTIPHARM Institutional Holdings Trend
AARTIPHARM Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 3.36%
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.29%
AARTIPHARM Shareholding Pattern
AARTIPHARM Shareholding Pattern
AARTIPHARM Shareholding History
AARTIPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in AARTIPHARM
Mutual Funds Invested in AARTIPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Aarti Pharmalabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4543% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 148/236 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1713% | Percentage of the fund’s portfolio invested in the stock 0.58% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/255 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0763% | Percentage of the fund’s portfolio invested in the stock 0.72% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/90 (+21) |
Compare 3-month MF holding change on Screener
smallcases containing AARTIPHARM stock
smallcases containing AARTIPHARM stock
Looks like this stock is not in any smallcase yet.
AARTIPHARM Events
AARTIPHARM Events
AARTIPHARM Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AARTIPHARM Dividend Trend
No dividend trend available
AARTIPHARM Upcoming Dividends
AARTIPHARM Upcoming Dividends
No upcoming dividends are available
AARTIPHARM Past Dividends
AARTIPHARM Past Dividends
Cash Dividend
Ex DateEx DateFeb 14, 2025
Interim
Interim | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Feb 14, 2025
Cash Dividend
Ex DateEx DateJul 31, 2024
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Jul 31, 2024
Cash Dividend
Ex DateEx DateFeb 16, 2024
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Feb 16, 2024
AARTIPHARM Stock News & Opinions
AARTIPHARM Stock News & Opinions
Articles & Videos
Spotlight
Aarti Pharmalabs Q4 PAT climbs 35% YoY to Rs 88 cr
Revenue from operations jumped 11.46% YoY to Rs 563.78 crore in in the quarter ended 31 March 2025. Profit before tax was at Rs 114.62 crore in the fourth quarter of FY25, up 19.70% from Rs 95.75 crore posted in the same period a year ago. Total expenses increased 8.61% to Rs 447.55 crore in Q4 FY25, compared to Rs 412.05 crore reported in Q4 FY24. The cost of material consumed stood at Rs 185.45 crore (down 7.97% YoY), employee benefit expenses were at Rs 43.37 crore (up 43.37% YoY) and finance costs stood at Rs 6.58 crore (up 40.59% YoY) during the period under review. On a full-year basis, the company's net profit rose 25.58% to Rs 272.40 crore on a 14.16% increase in revenue to Rs 2,115.07 crore in FY25 over FY24. The company's board has recommended a dividend of Rs 2.5 per equity share for the financial year 2024-25. Subject to the approval of the shareholders at the ensuing annual general meeting of the company. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The counter declined 1.33% to Rs 757.15 on the BSE. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Board of Aarti Pharmalabs recommends final dividend
Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 10 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Aarti Pharmalabs consolidated net profit rises 35.39% in the March 2025 quarter
Net profit of Aarti Pharmalabs rose 35.39% to Rs 88.34 crore in the quarter ended March 2025 as against Rs 65.25 crore during the previous quarter ended March 2024. Sales rose 11.47% to Rs 563.78 crore in the quarter ended March 2025 as against Rs 505.77 crore during the previous quarter ended March 2024. For the full year,net profit rose 25.59% to Rs 272.40 crore in the year ended March 2025 as against Rs 216.90 crore during the previous year ended March 2024. Sales rose 14.17% to Rs 2115.07 crore in the year ended March 2025 as against Rs 1852.61 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales563.78505.77 11 2115.071852.61 14 OPM %25.8323.24 -21.9620.84 - PBDT137.44114.87 20 447.59373.73 20 PBT114.6295.75 20 360.69300.49 20 NP88.3465.25 35 272.40216.90 26 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Aarti Pharmalabs to conduct board meeting
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 10 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Aarti Pharmalabs achieves SBTi approval for its emission reduction goals
Aarti Pharmalabs announced that its ambitious Science Based Targets (SBTs) for emissions have been officially approved by the Science Based Targets initiative (SBTi). This significant achievement underscores the company's deep commitment to environmental sustainability and proactive climate action, aligning its emission reduction goals with the objectives of the Paris Agreement. This approval encompasses all three emission scopes - Scope 1, Scope 2, and Scope 3 making Aarti Pharmalabs the 6th pharmaceutical company in India to achieve this comprehensive validation, a feat accomplished just three years after its 2022 demerger. The approval by SBTi, a globally recognized body that defines and promotes best practices in science-based target setting, validates Aarti Pharmalabs' dedication to contributing to a low-carbon economy. This milestone reflects the culmination of months of rigorous effort involving comprehensive carbon footprint assessment, the implementation of energy efficient initiatives across its operations, and active engagement with its value chain partners.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Aarti Pharmalabs spurts after Q3 PAT climbs 40% YoY to Rs 74 cr
Revenue from operations grew 19.9% to Rs 537.78 crore in the quarter ended 31 December 2024. Profit before tax was at Rs 100.63 crore in the third quarter of FY25, up 36.3% from Rs 73.82 crore posted in the same period a year ago. Total expenses increased 17.5% to Rs 442.18 crore in Q3 FY25, compared to Rs 376.26 crore reported in Q3 FY24. The cost of material consumed stood at Rs 261.19 crore (up 21.5% YoY), employee benefit expenses was at Rs 41.63 crore (up 15.1% YoY) and finance costs stood at Rs 9.97 crore (up 122.5% YoY) during the period under review. On nine-month basis, the company's consolidated net profit jumped 21.4% to Rs 184.06 crore in 9M FY25, compared to Rs 151.65 crore in 9M FY24. Revenue from operations rose 15.2% YoY to Rs 1,551.30 crore in 9M FY25. The company's board has declared an interim dividend of Rs 2.5 per equity share for the financial year 2024-25. The record date for the payment of the interim dividend has been set for Friday, 14 February 2025. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Aarti Pharmalabs consolidated net profit rises 40.24% in the December 2024 quarter
Net profit of Aarti Pharmalabs rose 40.24% to Rs 73.99 crore in the quarter ended December 2024 as against Rs 52.76 crore during the previous quarter ended December 2023. Sales rose 19.86% to Rs 537.78 crore in the quarter ended December 2024 as against Rs 448.69 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales537.78448.69 20 OPM %23.9121.32 - PBDT123.6692.59 34 PBT100.6373.82 36 NP73.9952.76 40 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Board of Aarti Pharmalabs recommends interim dividend
Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 5 February 2025, inter alia, have recommended the interim dividend of Rs 2.5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Aarti Pharmalabs to convene board meeting
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Aarti Pharmalabs closes operations of its Vapi plant under GPCB directives
Aarti Pharmalabs has closed the operations of its plant located Vapi, Gujarat following the directions received from the Gujarat Pollution Control Board (GPCB) under Section 33(A) of the Water (Prevention and Control of Pollution) Act, 1974, on 02 January 2025. Further, the GPCB has asked to submit a bank guarantee of Rs. 2,50,000/- for compliance assurance at the time of revocation and has also ordered to deposit interim Environment Damage Compensation amount as and when decided by the GPCB. Powered by Capital Market - Live
6 months agoCapital Market - Live
In last 6 months, promoter holding in the company has decreased by 1.81%
Pledged promoter holdings is insignificant